In summary, our studies indicate the preclinical efficacy of the CDK2/9 inhibitor fadraciclib as a single agent or in conjunction with frontline AML chemotherapeutics, highlighting its potential as a novel therapeutic approach. Here, CDK2 is linked to acute myeloid leukemia.